Iterum Therapeutics (Nasdaq:ITRM) - Aandelenkoers, Nieuws & Analyse

ITRM Overzicht aandelen

ITRM fundamentele analyse
Sneeuwvlok Score
Waardering	0/6
Toekomstige groei	2/6
Prestaties in het verleden	0/6
Financiële gezondheid	0/6
Dividenden	0/6

Beloningen

De omzet zal naar verwachting met 74.82% per jaar groeien

De winst is de afgelopen 5 jaar met 26% per jaar gegroeid

Risicoanalyse

Zeer volatiele aandelenkoers in de afgelopen 3 maanden

Heeft een omzet van minder dan 1 miljoen USD ( $0 )

Aandeelhouders zijn het afgelopen jaar substantieel verwaterd

Negatief eigen vermogen

+ 3 meer risico's

Iterum Therapeutics plc Concurrenten

Earth Science Tech

OTCPK:ETST

US$39.6m

Anebulo Pharmaceuticals

NasdaqCM:ANEB

US$36.3m

VYNE Therapeutics

NasdaqCM:VYNE

US$42.6m

Lexaria Bioscience

NasdaqCM:LEXX

US$37.2m

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Iterum Therapeutics
Historische aandelenkoersen
Huidige aandelenkoers	US$2.03
52 Week Hoogtepunt	US$2.39
52 Week Laag	US$0.81
Bèta	2.25
11 maand verandering	41.96%
3 maanden verandering	79.65%
1 Jaar Verandering	-2.87%
33 jaar verandering	-70.44%
5 jaar verandering	-95.08%
Verandering sinds IPO	-98.95%

Recent nieuws en updates

Recent updates

Despite Risks Around Regulatory Approval, Iterum Therapeutics Rates A Speculative Buy

Jul 05

It's Unlikely That The CEO Of Iterum Therapeutics plc (NASDAQ:ITRM) Will See A Huge Pay Rise This Year

Jun 11

Is Iterum Therapeutics (NASDAQ:ITRM) Using Debt Sensibly?

May 20

Have Insiders Been Selling Iterum Therapeutics plc (NASDAQ:ITRM) Shares?

Feb 04

This Insider Has Just Sold Shares In Iterum Therapeutics plc (NASDAQ:ITRM)

Feb 04

Iterum Therapeutics shares slide 13% on raising $10M

Feb 03

Iterum Therapeutics rises 39% on RA Capital stake disclosure

Dec 03

Iterum Therapeutics files US application for sulopenem in urinary tract infections

Nov 30

Iterum Therapeutics EPS beats by $0.45

Nov 16

Rendement voor aandeelhouders

	ITRM	US Pharmaceuticals	US Markt
7D	24.5%	4.2%	2.0%
1Y	-2.9%	13.7%	32.4%

Rendement versus industrie: ITRM presteerde slechter dan de US Pharmaceuticals -sector, die het afgelopen jaar een rendement van 13.7 % opleverde.

Rendement versus markt: ITRM presteerde slechter dan US Market, dat het afgelopen jaar een rendement van 32.4 % opleverde.

Prijsvolatiliteit

Is ITRM's price volatile compared to industry and market?
ITRM volatility
ITRM Average Weekly Movement	21.7%
Pharmaceuticals Industry Average Movement	9.7%
Market Average Movement	6.3%
10% most volatile stocks in US Market	15.9%
10% least volatile stocks in US Market	3.1%

Stabiele aandelenkoers: De aandelenkoers van ITRM is de afgelopen 3 maanden volatiel geweest.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit van ITRM is het afgelopen jaar gestegen van 15% naar 22%.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
2015	14	Corey Fishman	www.iterumtx.com

Iterum Therapeutics plc, een farmaceutisch bedrijf in een klinische fase, houdt zich bezig met de ontwikkeling en commercialisering van anti-infectiva in Ierland, Bermuda en de Verenigde Staten. Het ontwikkelt sulopenem, een nieuw anti-infectiemiddel met orale en intraveneuze formuleringen dat zich in Fase III van klinische studies bevindt voor de behandeling van ongecompliceerde infecties van de urinewegen, gecompliceerde infecties van de urinewegen en gecompliceerde intra-abdominale infecties. Het bedrijf werd opgericht in 2015 en heeft zijn hoofdkantoor in Dublin, Ierland.

Iterum Therapeutics plc Samenvatting

Hoe verhouden de winst en inkomsten van Iterum Therapeutics zich tot de beurswaarde?
ITRM fundamentele statistieken
Marktkapitalisatie	US$56.41m
Inkomsten(TTM)	-US$30.55m
Inkomsten(TTM)	n/a

0.0x

P/S-verhouding

-1.8x

Koers/Winstverhouding

Is ITRM overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
ITRM resultatenrekening (TTM)
Inkomsten	US$0
Kosten van inkomsten	US$0
Brutowinst	US$0
Overige uitgaven	US$30.55m
Inkomsten	-US$30.55m

Laatst gerapporteerde inkomsten

Sep 30, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-1.11
Brutomarge	0.00%
Nettowinstmarge	0.00%
Schuld/Eigen Vermogen Verhouding	-195.0%

Hoe presteerde ITRM op de lange termijn?

Bekijk historische prestaties en vergelijking

ITRM Overzicht aandelen

Beloningen

Risicoanalyse

Iterum Therapeutics plc Concurrenten

OTCPK:ETST

US$39.6m

NasdaqCM:ANEB

US$36.3m

NasdaqCM:VYNE

US$42.6m

NasdaqCM:LEXX

US$37.2m

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Iterum Therapeutics Regains Full Nasdaq Compliance with Listing Rule 5550(b)

Iterum Therapeutics plc to Report Q3, 2024 Results on Nov 14, 2024

Iterum Therapeutics plc Receives U.S. FDA Approval of ORLYNVAH (Oral Sulopenem) for the Treatment of Uncomplicated Urinary Tract Infections

Iterum Therapeutics Receives Formal Notice from Nasdaq Panel to Consider its Appeal at an Oral Hearing on November 21, 2024

Iterum Therapeutics Receives Delisting Determination Letter from Nasdaq Regarding its Failure to Meet the Terms of the Extension to Comply with the Minimum Stockholders’ Equity Requirement

New major risk - Shareholder dilution

Recent updates

Iterum Therapeutics Regains Full Nasdaq Compliance with Listing Rule 5550(b)

Iterum Therapeutics plc to Report Q3, 2024 Results on Nov 14, 2024

Iterum Therapeutics plc Receives U.S. FDA Approval of ORLYNVAH (Oral Sulopenem) for the Treatment of Uncomplicated Urinary Tract Infections

Iterum Therapeutics Receives Formal Notice from Nasdaq Panel to Consider its Appeal at an Oral Hearing on November 21, 2024

Iterum Therapeutics Receives Delisting Determination Letter from Nasdaq Regarding its Failure to Meet the Terms of the Extension to Comply with the Minimum Stockholders’ Equity Requirement

New major risk - Shareholder dilution

Forecast to breakeven in 2026

Iterum Therapeutics plc to Report Q2, 2024 Results on Aug 14, 2024

New major risk - Shareholder dilution

Iterum Therapeutics plc Broadens Patent Estate for Oral Sulopenem

New major risk - Financial position

Iterum Therapeutics plc Receives FDA Acceptance of Resubmission of NDA for Oral Sulopenem for the treatment of Uncomplicated Urinary Tract Infections

Iterum Therapeutics plc Announces Executive Changes

Iterum Therapeutics plc to Report Q1, 2024 Results on May 13, 2024

Iterum Therapeutics Resubmits New Drug Application to U.S. Food and Drug Administration for Oral Sulopenem

Iterum Therapeutics plc, Annual General Meeting, Jun 19, 2024

Insufficient new directors

Iterum Therapeutics plc to Report Q4, 2023 Results on Mar 28, 2024

Iterum Therapeutics plc Announces Positive Topline Results from Its Phase 3 Reassure Clinical Trial of Oral Sulopenem in Un Complicated Urinary Tract Infections

New major risk - Financial position

Iterum Therapeutics plc Announces the Resignation of Mark Chin as Director, Effective December 31, 2023

New major risk - Revenue and earnings growth

Iterum Therapeutics plc to Report Q3, 2023 Results on Nov 14, 2023

New minor risk - Share price stability

Iterum Therapeutics plc Announces Completion of Enrollment in its REASSURE Phase 3 Clinical Trial of Oral Sulopenem in Uncomplicated Urinary Tract Infections

Iterum Therapeutics Receives a Letter from the Listing Qualifications Department of the Nasdaq Stock Market

Iterum Therapeutics plc to Report Q2, 2023 Results on Aug 11, 2023

Iterum Therapeutics plc, Annual General Meeting, May 03, 2023

Iterum Therapeutics plc to Report Q3, 2022 Results on Nov 10, 2022

Iterum Announces First Patient Dosed in Reassure, A Phase 3 Clinical Trial of Oral Sulopenem in Uncomplicated Urinary Tract Infections

Iterum Therapeutics plc Announces Issuance of Allowance for A U.S. Patent Covering Oral Sulopenem

Iterum Therapeutics Regains Compliance with Nasdaq Bid Price Rule

Does Iterum Therapeutics (NASDAQ:ITRM) Have A Healthy Balance Sheet?

Iterum Therapeutics Non-GAAP EPS of -$0.03 beats by $0.03

Iterum Therapeutics plc Announces Special Protocol Assessment Agreement with the FDA

Iterum jumps 64% as FDA agrees to Phase 3 trial for UTI candidate

Does Iterum Therapeutics (NASDAQ:ITRM) Have A Healthy Balance Sheet?

Iterum Therapeutics plc, Annual General Meeting, Jun 15, 2022

Iterum Therapeutics plc to Report Q4, 2021 Results on Mar 28, 2022

Does Iterum Therapeutics (NASDAQ:ITRM) Have A Healthy Balance Sheet?

Iterum Therapeutics Provides Update from FDA Type A Meeting Regarding Oral Sulopenem

Is Iterum Therapeutics (NASDAQ:ITRM) A Risky Investment?

Bernstein Liebhard Reminds Investors of the Deadline to File Lead Plaintiff Motion in Securities Class Action Lawsuit Filed Against Iterum Therapeutics plc

Pomerantz Law Firm Announces the Filing of Class Action against Iterum Therapeutics plc and Certain Officers

Despite Risks Around Regulatory Approval, Iterum Therapeutics Rates A Speculative Buy

Iterum Therapeutics plc Receives Letter from the U.S. Food and Drug Administration as Part of Their Ongoing Review of the New Drug Application for sulopenem etzadroxil/probenecid

Independent Director Mohammed Shahzad Malik has left the company

It's Unlikely That The CEO Of Iterum Therapeutics plc (NASDAQ:ITRM) Will See A Huge Pay Rise This Year

Consensus forecasts updated

Iterum Therapeutics plc Provides Update on NDA Review

Is Iterum Therapeutics (NASDAQ:ITRM) Using Debt Sensibly?

Price target increased to US$2.00

Consensus revenue estimates increase to US$2.86m

Independent Director has left the company

Iterum Therapeutics Appoints Beth P. Hecht to Board of Directors

Iterum Therapeutics plc to Report Q4, 2020 Results on Mar 12, 2021

New 90-day high: US$2.27

Have Insiders Been Selling Iterum Therapeutics plc (NASDAQ:ITRM) Shares?

This Insider Has Just Sold Shares In Iterum Therapeutics plc (NASDAQ:ITRM)